Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex cash
Cash and short-term investments held at the end of each period.
Scilex's cash was $566.00K at Jun 30, 2026. For fiscal 2025 it was $4.96M, up 51.4% from the year before. The highest annual figure on record is $55.50M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.96M | +51.4% |
| FY2024 | Dec 31, 2024 | $3.27M | -30.8% |
| FY2023 | Dec 31, 2023 | $4.73M | +116.5% |
| FY2022 | Dec 31, 2022 | $2.18M | -52.9% |
| FY2021 | Dec 31, 2021 | $4.64M | -4.1% |
| FY2020 | Dec 31, 2020 | $4.84M | -91.3% |
| FY2019 | Dec 31, 2019 | $55.50M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $566.00K | -86.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.35M | -42.2% |
| Q4 FY2025 | Dec 31, 2025 | $4.96M | +51.4% |
| Q3 FY2025 | Sep 30, 2025 | $878.00K | -89.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.10M | -57.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.80M | +109.1% |
| Q4 FY2024 | Dec 31, 2024 | $3.27M | -30.8% |
| Q3 FY2024 | Sep 30, 2024 | $8.12M | +309.9% |
| Q2 FY2024 | Jun 30, 2024 | $9.67M | -72.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.77M | -45.3% |
| Q4 FY2023 | Dec 31, 2023 | $4.73M | +116.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.98M | -20.3% |
| Q2 FY2023 | Jun 30, 2023 | $35.13M | +414.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.07M | -84.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.18M | -52.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.48M | -98.2% |
| Q2 FY2022 | Jun 30, 2022 | $6.83M | -95.1% |
| Q1 FY2022 | Mar 31, 2022 | $33.57M | -76.0% |
| Q4 FY2021 | Dec 31, 2021 | $4.64M | -4.1% |
| Q3 FY2021 | Sep 30, 2021 | $139.52M | +176814.5% |
| Q2 FY2021 | Jun 30, 2021 | $139.66M | +151.7% |
| Q1 FY2021 | Mar 31, 2021 | $139.71M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.84M | – |
| Q3 FY2020 | Sep 30, 2020 | $78.87K | – |
| Q4 FY2019 | Dec 31, 2019 | $55.50M | – |